First Time Loading...

Genmab A/S
NASDAQ:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
NASDAQ:GMAB
Watchlist
Price: 27.75 USD 1.87% Market Closed
Updated: Jul 21, 2024
Have any thoughts about
Genmab A/S?
Write Note

Wall Street
Price Targets

GMAB Price Targets Summary
Genmab A/S

Wall Street analysts forecast GMAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GMAB is 165.42 USD with a low forecast of 7.68 USD and a high forecast of 509.45 USD.

Lowest
Price Target
7.68 USD
72% Downside
Average
Price Target
165.42 USD
496% Upside
Highest
Price Target
509.45 USD
1 736% Upside

GMAB Last Price Targets
Genmab A/S

The latest public price target was made on Jun 27, 2024 by Kaveri Pohlman from BTIG , who expects GMAB stock to rise by 69% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
Kaveri Pohlman
BTIG
47 USD
Upside 69%
3 weeks ago
Jun 27, 2024
Genmab price target raised to $47 from $46 at BTIG
TheFly
Raghuram Selvaraju
H.C. Wainwright
50 USD
Upside 80%
3 weeks ago
Jun 27, 2024
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
StreetInsider
Asthika Goonewardene
Truist Financial
53 USD
Upside 91%
1 month ago
Jun 4, 2024
Genmab price target raised to $53 from $50 at Truist
TheFly
Unknown Analyst
Leerink Partners
36 USD
Upside 30%
1 year ago
Feb 6, 2023
SVB Leerink Maintains Market Perform on Genmab, Raises Price Target to $36
Benzinga
Kaveri Pohlman
BTIG
Price Target 47 USD
Upside/Downside 69%
View Source
Raghuram Selvaraju
H.C. Wainwright
Price Target 50 USD
Upside/Downside 80%
View Source
Asthika Goonewardene
Truist Financial
Price Target 53 USD
Upside/Downside 91%
View Source
Unknown Analyst
Leerink Partners
Price Target 36 USD
Upside/Downside 30%
View Source
Genmab A/S Competitors:
Price Targets
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
30% Upside
144510
GC Cell Corp
124% Upside
AVCT
Avacta Group PLC
17% Downside
CDMO
Avid Bioservices Inc
35% Upside
VYGR
Voyager Therapeutics Inc
114% Upside
OCX
OncoCyte Corp
29% Upside
688428
InnoCare Pharma Ltd
60% Upside
EXEL
Exelixis Inc
20% Upside

Revenue
Forecast

Revenue Estimate
Genmab A/S

For the last 8 years the compound annual growth rate for Genmab A/S's revenue is 40%. The projected CAGR for the next 3 years is 19%.

40%
Past Growth
19%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Genmab A/S

For the last 8 years the compound annual growth rate for Genmab A/S's operating income is 28%. The projected CAGR for the next 3 years is 24%.

28%
Past Growth
24%
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

Net Income Estimate
Genmab A/S

For the last 8 years the compound annual growth rate for Genmab A/S's net income is 24%. The projected CAGR for the next 3 years is 26%.

24%
Past Growth
26%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GMAB's stock price target?
Price Target
165.42 USD

According to Wall Street analysts, the average 1-year price target for GMAB is 165.42 USD with a low forecast of 7.68 USD and a high forecast of 509.45 USD.

What is Genmab A/S's Revenue forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for Genmab A/S's revenue is 40%. The projected CAGR for the next 3 years is 19%.

What is Genmab A/S's Operating Income forecast?
Projected CAGR
24%

For the last 8 years the compound annual growth rate for Genmab A/S's operating income is 28%. The projected CAGR for the next 3 years is 24%.

What is Genmab A/S's Net Income forecast?
Projected CAGR
26%

For the last 8 years the compound annual growth rate for Genmab A/S's net income is 24%. The projected CAGR for the next 3 years is 26%.